}

Minapharm Pharmaceuticals logs higher consolidated revenues in Q1 2026

Updated 8/17/2026 11:27:00 AM
Minapharm Pharmaceuticals logs higher consolidated revenues in Q1 2026

Arab Finance: Minapharm Pharmaceuticals swung to consolidated net profits attributable to the parent company at EGP 66.958 million in the first quarter (Q1) of 2026, against net losses of EGP 253.302 million in Q1 2025, according to the financial results.  

Earnings per share (EPS) hit EGP 5.29 at the end of March 2026 when compared to a loss per share of EGP 22.89 in the year-ago period.

Net revenues increased to EGP 1.818 billion in Q1 2026 from EGP 1.607 billion in Q1 2025.

Regarding the standalone results, the company also turned profitable at EGP 71.763 million, against standalone net losses of EGP 247.507 million at the end of March 2025.

Related News